USPTO 2015–2025 USPTO PatentsView US Corporation

Cancer Prevention Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Cancer ranks #45,443 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.

#45,443
of 49,997 US assignees by volume
30th percentile
by Innovation Score (29.3/100)
19.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R45443 · US Corporation #45,443 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #45,443/49,997
  • PHOTO-FINISH Campagnie Generale…
  • CPC-NARROW A61P · 2 areas
  • INNOV-THIN 29.3/100
  • CLAIMS-RICH 19.0 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Campagnie Generale Des Etablissements Michelin (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Cancer

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Cancer's Innovation Score is 29.3/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Cancer's grants concentrate

Cancer Prevention Pharmaceuticals, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2022. By volume, Cancer sits between Campagnie Generale Des Etablissements Michelin and Canna-Chemistries LLC.

Cancer's three-year grant acceleration

Cancer Prevention Pharmaceuticals, Inc. shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Cancer's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Cancer holds 5 patents at rank #45,730, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Cancer

By rank, the assignees closest to #45,730 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Cancer's primary technology class.

Cancer's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2021202220242025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Cancer Prevention Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 2 40.0%
2022 1 20.0%
2024 1 20.0%
2025partial year 1 20.0%

Which technologies does Cancer Prevention Pharmaceuticals, Inc. patent most?

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#45,443

of 49,997 tracked assignees

Innovation Score

29.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Cancer Prevention Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • Cancer Prevention Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #45,443 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Cancer Prevention Pharmaceuticals, Inc. against Campagnie Generale Des Etablissements Michelin, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 29.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.